Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment

References

• Arnedo M, Taffé P, Sahli R, Furrer H, Hirschel B, Elzi L, . 2007. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics 17:755–764.
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Ustundag B. 2003. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64:598–604.
   PubMed Web of Science ®Google Scholar
• Chien KL, Fang WH, Wen HC, Lin HP, Lin YL, Lin SW, . 2008. APOA1/C3/A5 haplotype and risk of hypertriglyceridemia in Taiwanese. Clin Chim Acta 390:56–62.
   Google Scholar
• Diaz FJ, Meary A, Arranz MJ, Ruaño G, Windemuth A, de Leon J. 2009. Acetyl-coenzyme A carboxylase alpha gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels. Schizophr Res 115:136–140.
   Google Scholar
• Dichlberger A, Cogburn LA, Nimpf J, Schneider WJ. 2007. Avian apolipoprotein A-V binds to LDL receptor gene family members. J Lipid Res 48:1451–1456.
   Google Scholar
• Elosua R, Ordovas JM, Cupples LA, Lai CQ, Demissie S, Fox CS, . 2006. Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study. J Lipid Res 47:990–996.
   PubMedGoogle Scholar
• Gaulin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL. 1999. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 156:1270–1272.
   PubMed Web of Science ®Google Scholar
• Ghaeli P, Dufresne RL. 1996. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 53:2079–2081.
   PubMed Web of Science ®Google Scholar
• Ghaeli P, Dufresne RL. 1999. Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacotherapy 19:1099–1101.
   PubMed Web of Science ®Google Scholar
• Guardiola M, Ferré R, Salazar J, Alonso-Villaverde C, Coll B, Parra S, . 2006. Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation. Clin Chem 52:1914–1919.
   Google Scholar
• Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, . 2000. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 157:975–981.
   PubMed Web of Science ®Google Scholar
• Hong CJ, Liou YJ, Bai YM, Chen TT, Wang YC, Tsai SJ. 2010. Dopamine receptor D2 (DRD2) gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics 20:359–66.
   PubMed Web of Science ®Google Scholar
• Jang Y, Paik JK, Hyun YJ, Chae JS, Kim JY, Choi JR, . 2009. The apolipoprotein A5 –1131T>C promoter polymorphism in Koreans: association with plasma APOA5 and serum trigly ceride concentrations, LDL particle size and coronary artery disease. Clin Chim Acta 402:83–87.
   Google Scholar
• Kane JM, Barrett EJ, Casey DE, Correll CU, Gelenberg AJ, Klein S, . 2004. Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 65:1447–1455.
   PubMed Web of Science ®Google Scholar
• Kuzman MR, Medved V, Bozina N, Grubi in J, Jovanovic N, Sertic J. 2011. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogenomics 11:35–44.
   Google Scholar
• Lai CQ, Arnett DK, Corella D, Straka RJ, Tsai MY, Peacock JM, . 2007. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler Thromb Vasc Biol 27:1417–1425.
   PubMed Web of Science ®Google Scholar
• Lee E, Chow LY, Leung CM. 2011. Metabolic profile of first and second generation antipsychotics among Chinese patients. Psychiatry Res 185:456–458.
   Google Scholar
• Lewis GF, Steiner G. 1996. Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 12:37–56.
   Google Scholar
• Liu ZK, Hu M, Baum L, Thomas GN, Tomlinson B. 2010. Associations of polymorphisms in the apolipoprotein A1/C3/A4/A5 gene cluster with familial combined hyperlipidaemia in Hong Kong Chinese. Atherosclerosis 208;427–432.
   Google Scholar
• Melkersson KI, Scordo MG, Gunes A, Dahl ML. 2007. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry 68:697–704.
   PubMed Web of Science ®Google Scholar
• Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, . 2005. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 280;21553–21560.
   Google Scholar
• Newcomer JW. 2005. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl 1):1–93.
   PubMed Web of Science ®Google Scholar
• Nilsson SK, Lookene A, Beckstead JA, Gliemann J, Ryan RO, Olivecrona G. 2007. Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Biochemistry 46:3896–3904.
   Google Scholar
• Osser DN, Najarian DM, Dufresne RL. 1999. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 60:767–770.
   PubMed Web of Science ®Google Scholar
• Palmen J, Smith AJ, Dorfmeister B, Putt W, Humphries SE, Talmud PJ. 2008. The functional interaction on in vitro gene expression of APOA5 SNPs, defining haplotype APOA52, and their paradoxical association with plasma triglyceride but not plasma apoAV levels. Biochim Biophys Acta 1782: 447–452.
   Google Scholar
• Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, . 2001. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294:169–173.
   PubMed Web of Science ®Google Scholar
• Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B. 2008. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J 8: 228–236.
   PubMed Web of Science ®Google Scholar
• Storey JD. 2002. A direct approach to false discovery rate. J R Statist Soc B 64:479–498.
   Google Scholar
• Suchanek P, Lorenzova A, Poledne R, Hubacek JA. 2008. Changes of plasma lipids during weight reduction in females depends on APOA5 variants. Ann Nutr Metab 53:104–108.
   Google Scholar
• Tai ES, Ordovas JM. 2008. Clinical significance of apolipoprotein A5. Curr Opin Lipidol 19:349–354.
   PubMed Web of Science ®Google Scholar
• Talmud PJ. 2001. Genetic determinants of plasma triglycerides: impact of rare and common mutations. Curr Atheroscler Rep 3:191–199.
   Google Scholar
• Talmud PJ, Palmen J, Putt W, Lins L, Humphries SE. 2005. Determination of the functionality of common APOA5 polymorphisms. J Biol Chem 280:28215–28220.
   Web of Science ®Google Scholar
• Wang YC, Bai YM, Chen JY, Lin CC, Lai IC, Liou YJ. 2005. C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population. Pharmacogenet Genomics 15:743–748.
   PubMed Web of Science ®Google Scholar